Results of operation - Research and development expenses (Details) - EUR (€) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Disclosure of research and development expenses [Line items] | ||||
| Staff costs | € 11,992,000 | € 10,026,000 | € 23,493,000 | € 21,550,000 |
| Capitalized costs | (700,000) | (154,000) | (1,600,000) | |
| Total research and development expenses | 9,543,000 | 10,059,000 | 18,347,000 | 19,048,000 |
| Increase (Decrease) in research and development expense. | € (1,200,000) | € (2,100,000) | ||
| Percentage of increase (decrease) in research and development expense. | (11.20%) | (10.20%) | ||
| Research and Development Expenses Before Capitalization | € 9,500,000 | 10,800,000 | € 18,500,000 | 20,600,000 |
| Research & Development | ||||
| Disclosure of research and development expenses [Line items] | ||||
| Staff costs | 3,050,000 | 3,700,000 | 5,775,000 | 8,280,000 |
| Consulting and contractors' fees | 2,234,000 | 3,004,000 | 4,246,000 | 3,877,000 |
| Q&A regulatory | 91,000 | 43,000 | 99,000 | 119,000 |
| Depreciation and amortization expense | 1,470,000 | 418,000 | 2,746,000 | 829,000 |
| Travel | 352,000 | 434,000 | 737,000 | 713,000 |
| Manufacturing and outsourced development | 803,000 | 1,292,000 | 1,912,000 | 2,600,000 |
| Clinical studies | 1,049,000 | 1,396,000 | 2,073,000 | 3,250,000 |
| IT | 150,000 | 39,000 | 218,000 | 68,000 |
| Rent | 252,000 | 104,000 | 461,000 | 227,000 |
| Other expenses | 92,000 | 320,000 | 234,000 | 639,000 |
| Capitalized costs | (691,000) | (154,000) | (1,554,000) | |
| Total research and development expenses | € 9,543,000 | € 10,059,000 | € 18,347,000 | € 19,048,000 |